Table 3 Base case results of the model
Model outcomes | Nivolumab + chemotherapy | Chemotherapy alone |
|---|---|---|
US | ||
Total costs ($) | 326,032.70 | 108,892.05 |
Incremental costs | 217,140.65 | - |
Total effectiveness (QALYs) | 1.12 | 0.89 |
Incremental effectiveness (QALYs) | 0.23 | - |
ICER ($/QALY) | 944,089.78 | Â |
China | ||
Total costs ($) | 113,897.45 | 14,954.89 |
Incremental costs | 98,942.56 | - |
Total effectiveness (QALYs) | 1.12 | 0.89 |
Incremental effectiveness (QALYs) | 0.23 | - |
ICER ($/QALY) | 430,185.04 | Â |